Public Law 114-146 | Public Law 114–146: To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

As enacted: this collection preserves GovInfo's listed Beta USLM public-law XML, including printed amendment instructions and legislative history. Later amendments are not consolidated here; availability in this XML inventory does not establish completeness of all laws enacted by Congress.

PUBLIC LAW 114–146—APR. 19, 2016

130 STAT. 357

Public Law

114–146

114th Congress

An Act

To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

Apr. 19, 2016

[S. 2512]

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

Adding

Zika Virus to the FDA Priority Review Voucher Program Act.

SECTION 1.

21 USC 301 note.

SHORT TITLE.

This Act may be cited as the “

Adding Zika Virus to the FDA Priority Review Voucher Program Act

”.

SEC. 2.

EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3))

is amended

—

(1)

redesignating

subparagraph (R) as subparagraph (S);

(2)

in subparagraph (Q), by

striking

“Filoviruses” and

inserting

“Filovirus Diseases”; and

(3)

inserting

after subparagraph (Q) the following:

“(R)

Zika Virus Disease.”

Approved April 19, 2016.

LEGISLATIVE HISTORY—S. 2512:

CONGRESSIONAL RECORD, Vol. 162 (2016):

Mar. 17, considered and passed Senate.

Apr. 12, considered and passed House.

○